134 related articles for article (PubMed ID: 30839339)
61. Expression of MCM-3 and MCM-7 in Primary Cutaneous T-cell Lymphomas.
Jankowska-Konsur A; Kobierzycki C; Reich A; Grzegrzolka J; Maj J; Dziegiel P
Anticancer Res; 2015 Nov; 35(11):6017-26. PubMed ID: 26504025
[TBL] [Abstract][Full Text] [Related]
62. The prognostic value of membrane markers and morphometric characteristics of lymphoid cells in blood and lymph nodes from patients with mycosis fungoides.
van der Loo EM; Meijer CJ; Scheffer E; van Vloten WA
Cancer; 1981 Aug; 48(3):738-44. PubMed ID: 6454478
[TBL] [Abstract][Full Text] [Related]
63. Leonine facies (LF) and mycosis fungoides (MF): A single-center study and systematic review of the literature.
Brown DN; Wieser I; Wang C; Dabaja BS; Duvic M
J Am Acad Dermatol; 2015 Dec; 73(6):976-86. PubMed ID: 26476898
[TBL] [Abstract][Full Text] [Related]
64. Immune privilege disruption in folliculotropic mycosis fungoides: investigation of major histocompatibility complex antigen expression.
Deonizio JMD; Guitart J; Yazdan P; Mulinari-Brenner F; Sotto MN; Sanches JA
Int J Dermatol; 2018 Jun; 57(6):675-680. PubMed ID: 29603194
[TBL] [Abstract][Full Text] [Related]
65. Leu-8 and Leu-9 antigen phenotypes: immunologic criteria for the distinction of mycosis fungoides from cutaneous inflammation.
Wood GS; Abel EA; Hoppe RT; Warnke RA
J Am Acad Dermatol; 1986 Jun; 14(6):1006-13. PubMed ID: 3088069
[TBL] [Abstract][Full Text] [Related]
66. CCR7 expression correlates with subcutaneous involvement in mycosis fungoides skin lesions and promotes migration of mycosis fungoides cells (MyLa) through mTOR activation.
Hu SC; Lin CL; Hong CH; Yu HS; Chen GS; Lee CH
J Dermatol Sci; 2014 Apr; 74(1):31-8. PubMed ID: 24411580
[TBL] [Abstract][Full Text] [Related]
67. TOX expression in different subtypes of cutaneous lymphoma.
Morimura S; Sugaya M; Suga H; Miyagaki T; Ohmatsu H; Fujita H; Asano Y; Tada Y; Kadono T; Sato S
Arch Dermatol Res; 2014 Nov; 306(9):843-9. PubMed ID: 25216799
[TBL] [Abstract][Full Text] [Related]
68. Pigmented purpuric dermatitis preceding the diagnosis of mycosis fungoides by 24 years.
Viseux V; Schoenlaub P; Cnudde F; Le Roux P; Leroy JP; Plantin P
Dermatology; 2003; 207(3):331-2. PubMed ID: 14571083
[No Abstract] [Full Text] [Related]
69. Mycosis fungoides in young patients: clinical characteristics and outcome.
Crowley JJ; Nikko A; Varghese A; Hoppe RT; Kim YH
J Am Acad Dermatol; 1998 May; 38(5 Pt 1):696-701. PubMed ID: 9591813
[TBL] [Abstract][Full Text] [Related]
70. Clinicopathologic features and T-cell receptor gene rearrangement findings of mycosis fungoides palmaris et plantaris.
Kim ST; Jeon YS; Sim HJ; Kim SH; Kim YK; Suh KS; Park JH; Park SW
J Am Acad Dermatol; 2006 Mar; 54(3):466-71. PubMed ID: 16488298
[TBL] [Abstract][Full Text] [Related]
71. The pigmented and purpuric dermatitis and the many faces of mycosis fungoides.
Lipsker D
Dermatology; 2003; 207(3):246-7. PubMed ID: 14571063
[No Abstract] [Full Text] [Related]
72. Overexpression of hypoxia-inducible factor 1 alpha impacts FoxP3 levels in mycosis fungoides--cutaneous T-cell lymphoma: clinical implications.
Alcántara-Hernández M; Torres-Zárate C; Pérez-Montesinos G; Jurado-Santacruz F; Domínguez-Gómez MA; Peniche-Castellanos A; Ferat-Osorio E; Neri N; Nambo MJ; Alvarado-Cabrero I; Moreno-Lafont M; Huerta-Yepez S; Bonifaz LC
Int J Cancer; 2014 May; 134(9):2136-45. PubMed ID: 24127318
[TBL] [Abstract][Full Text] [Related]
73. Comparative morphometric analysis of intraepidermal and dermal lymphocytes in early mycosis fungoides and some inflammatory dermatoses.
Gamsizkan M; Demiriz M; Karslioğlu Y; Günhan O
Anal Quant Cytol Histol; 2007 Jun; 29(3):153-8. PubMed ID: 17672375
[TBL] [Abstract][Full Text] [Related]
74. Ichthyosiform mycosis fungoides.
Badawy E; D'Incan M; El Majjaoui S; Franck F; Fabricio L; Dereure O; Souteyrand P; Guillot B
Eur J Dermatol; 2002; 12(6):594-6. PubMed ID: 12459538
[TBL] [Abstract][Full Text] [Related]
75. Mycosis Fungoides Manifesting as Giant Cell Lichenoid Dermatitis.
Belousova IE; Khairutdinov VR; Bessalova A; Kazakov DV
Am J Dermatopathol; 2018 Apr; 40(4):283-285. PubMed ID: 29135510
[TBL] [Abstract][Full Text] [Related]
76. Vascular endothelial growth factor A (VEGFA) expression in mycosis fungoides.
Pileri A; Agostinelli C; Righi S; Fuligni F; Bacci F; Sabattini E; Patrizi A; Pileri SA; Piccaluga PP
Histopathology; 2015 Jan; 66(2):173-81. PubMed ID: 24766213
[TBL] [Abstract][Full Text] [Related]
77. Decreased progranulin expression in Mycosis fungoides: a possible association with the high frequency of skin infections.
Nakajima R; Miyagaki T; Kamijo H; Oka T; Shishido-Takahashi N; Suga H; Sugaya M; Sato S
Eur J Dermatol; 2018 Dec; 28(6):790-794. PubMed ID: 30530405
[TBL] [Abstract][Full Text] [Related]
78. miRNA in mycosis fungoides and skin inflammation.
Persson JL
APMIS; 2013 Nov; 121(11):1017-9. PubMed ID: 24106870
[TBL] [Abstract][Full Text] [Related]
79. Large-cell transformation of mycosis fungoides-differential diagnosis with implications for clinical management: a consensus statement of the US Cutaneous Lymphoma Consortium.
Kadin ME; Hughey LC; Wood GS
J Am Acad Dermatol; 2014 Feb; 70(2):374-6. PubMed ID: 24438952
[No Abstract] [Full Text] [Related]
80. Relationship Between Pityriasis Lichenoides and Mycosis Fungoides: A Clinicopathological, Immunohistochemical, and Molecular Study.
Zaaroura H; Sahar D; Bick T; Bergman R
Am J Dermatopathol; 2018 Jun; 40(6):409-415. PubMed ID: 29210716
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
